Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase II Prospective Study Of Lucanoximab Combined With Tagolimab As Neoadjuvant Therapy For Resectable Head And Neck Squamous Cell Carcinoma

NCT07492914 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07492914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase II Prospective Study Of Lucanoximab Combined With Tagolimab As Neoadjuvant Therapy For Resectable Head And Neck Squamous Cell Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 11, 2026
Completion date
March 31, 2031
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable head and neck squamous cell carcinoma